No

Antihemophilic Agent; Blood Product Derivative

Patients with factor VIII inhibitors who are to undergo surgery or those who are bleeding

C

Disseminated intravascular coagulation; patients with normal coagulation mechanism

Products are prepared from pooled human plasma; such plasma may contain the causative agents of viral diseases. Tests used to control efficacy such as APTT, WBCT, and TEG do not correlate with clinical efficacy. Dosing to normalize these values may result in DIC. Identification of the clotting deficiency as caused by factor VIII inhibitors is essential prior to starting therapy. Use with extreme caution in patients with impaired hepatic function.

<1%: Hypotension, flushing, fever, headache, chills, rash, urticaria, disseminated intravascular coagulation, anaphylaxis, indications of protein sensitivity

Rapid infusion may cause hypotension, excessive administration can cause DIC

Store at 2°C to 8°C (36°F to 46°F); use within 1-3 hours after reconstitution

Dosage range: 25-100 factor VIII correctional units per kg depending on the severity of hemorrhage

PT, PTT, WBCT, fibrin, platelets, fibrin split products

None reported

None reported

No information available to require special precautions

No effects or complications reported

This medication can only be given I.V. Immediately report backache, itching or rash, difficulty breathing, acute feelings of anxiety, or sudden onset headache. Pregnancy/breast-feeding precautions: Inform prescriber if you are pregnant. Consult prescriber if breast-feeding.

Monitor for hypotension, may reinitiate infusion at a slower rate; have epinephrine ready to treat hypersensitivity reactions

Injection:

Feiba VH Immuno®, heparin free: Each bottle is labeled with correctional units of Factor VIII